Exercise-Inspired Pill in Human Trials Could Aid Weight Maintenance

A U.S. biotechnology company, Enveda, is developing an experimental oral medication, ENV-308, that mimics a natural bodily signal produced during exercise. The drug's goal is not to replicate all effects of physical activity but to imitate the action of a molecule known as Lac-Phe. This molecule is released during exercise and has been associated with reduced appetite and influencing food consumption and body weight in animal studies.

“

The experimental drug is called ENV-308 and is being developed by the American company Enveda.

ENV-308 is designed to deliver these effects in a daily tablet form, acting on leptin, a hormone involved in regulating satiety. The company's Phase 1 clinical study involved 88 participants without obesity. Initial findings indicate the drug was well-tolerated, with no significant gastrointestinal issues reported. While the primary goal of this early stage was to assess safety and tolerability, researchers did observe changes in leptin levels, particularly in individuals with higher baseline levels of the hormone.

“

The idea is not to reproduce all the effects of sport, but to imitate the action of a molecule naturally produced by the body, called Lac-Phe.

Enveda hopes ENV-308 could eventually be used for weight maintenance, particularly after treatments with GLP-1 medications. A key challenge in obesity treatment is regaining weight after discontinuing such therapies. The company plans to investigate whether ENV-308 can help sustain weight loss and preserve muscle mass, effects that were observed in animal studies but require further human clinical investigation.

“

According to the company, the drug was well tolerated and no significant gastrointestinal problems were observed.

Leptin, the hormone targeted by ENV-308, plays a crucial role in signaling the brain about the body's fat stores and regulating appetite. In cases of obesity, leptin levels can rise, but the body may become less sensitive to it, a condition known as leptin resistance. The development of ENV-308 is part of ongoing research into novel approaches for appetite and weight management.

“

Enveda aims for ENV-308 to be used in the future for weight maintenance after treatments with GLP-1 type drugs.